Pages that link to "Q71691648"
Jump to navigation
Jump to search
The following pages link to Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response (Q71691648):
Displaying 50 items.
- First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study (Q24812405) (← links)
- Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group (Q33328282) (← links)
- Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group (Q33330720) (← links)
- Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study (Q33334489) (← links)
- Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck (Q33335541) (← links)
- Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer (Q33500301) (← links)
- Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients (Q33500968) (← links)
- Paclitaxel by 3-H infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group (Q33501679) (← links)
- Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. (Q33501861) (← links)
- Salvage Chemotherapy With Paclitaxel, Vinorelbine, and Cisplatin (PVC) in Anthracycline-Resistant Advanced Breast Cancer (Q33502773) (← links)
- Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study (Q33503243) (← links)
- Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group (Q33504589) (← links)
- Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study (Q33506194) (← links)
- A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer (Q33573920) (← links)
- Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy (Q33737986) (← links)
- Risks and benefits of taxanes in breast and ovarian cancer (Q34086098) (← links)
- Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience (Q34273153) (← links)
- Paclitaxel: epirubicin in metastatic breast cancer--a review (Q34296771) (← links)
- The Role of Plant-Derived Drugs and Herbal Medicines in Healthcare (Q34451466) (← links)
- The taxoids. Comparative clinical pharmacology and therapeutic potential (Q34456149) (← links)
- Breast cancer survival and in vitro tumor response in the extreme drug resistance assay (Q34647221) (← links)
- Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer (Q35035776) (← links)
- The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer (Q35110201) (← links)
- Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions (Q35182946) (← links)
- Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer (Q35692392) (← links)
- Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab (Q36132952) (← links)
- Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil (Q36217005) (← links)
- Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety (Q36625974) (← links)
- Taxanes in breast cancer: an update (Q36681504) (← links)
- Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer (Q36697132) (← links)
- Weekly docetaxel in the treatment of metastatic breast cancer (Q37052871) (← links)
- Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network (Q40570268) (← links)
- Paclitaxel Activity in Anthracycline Refractory Breast Cancer Patients (Q40651062) (← links)
- Systemic treatment for stage I and stage II breast cancer. (Q40881808) (← links)
- Paclitaxel Formulation as a Cause of Ethanol Intoxication (Q41529104) (← links)
- A Comparative Review of Colony-Stimulating Factors (Q41634907) (← links)
- Anthracyclines-paclitaxel combinations in the treatment of breast cancer. (Q41663662) (← links)
- Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes (Q41704931) (← links)
- Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer (Q41714204) (← links)
- A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines (Q43293573) (← links)
- A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma (Q43947289) (← links)
- A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer (Q44325856) (← links)
- Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study (Q44369766) (← links)
- Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies. (Q46015623) (← links)
- An exploratory study of frequent pain measurement in a cancer clinical trial (Q52007040) (← links)
- Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. (Q54031367) (← links)
- Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. (Q54116133) (← links)
- A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer (Q57265732) (← links)
- Personalized medicine in breast cancer: pharmacogenomics approaches. (Q64934294) (← links)
- Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma (Q71760918) (← links)